Peter W Groeneveld

Dados Biográficos

ID5144297
NOMEPeter W Groeneveld
PRENOMESPeter W
SOBRENOMEGroeneveld
ASSINATURAGROENEVELD P W
AFILIAÇÕESUniversity of Pennsylvania
ORCID0000-0002-7374-4292
VERIFICADOSim
TOTAL DE OBRAS9
TOTAL DE CITAÇÕES2
TOTAL COMO AUTOR9
TOTAL COMO EDITOR0
PRIMEIRO ANO DE PUBLICAÇÃO2005
ANO MAIS RECENTE DE PUBLICAÇÃO2026
ÍNDICE H1

  • Housing Cost Burden and Outcomes Among Medicaid Beneficiaries With Heart Failure

    Open AccessJoniqua N Ceasar, Lin Yang et al.ARTICLEJAMA Health Forum2026

    The findings of this study suggest that area-level housing cost burden may be associated with outcomes among Medicaid beneficiaries with HF and highlights the need to investigate whether strategies that address housing affordability can play a role in improving health outcomes in this population

  • Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US

    Open AccessLauren A Eberly, Lin Yang et al.ARTICLEJAMA Health Forum2021

    In this cohort study of US patients with T2D, GLP-1 RA use increased, but remained low overall for treatment of T2D, particularly among patients with ASCVD who are likely to derive the most benefit. Asian, Black, and Hispanic patients and those with low income were less likely to receive treatment with a GLP-1 RA. Strategies to lower barriers to GLP-1 RA use, such as lower cost, are needed to prevent the widening of well-documented inequities in …

  • The Effects of Market Competition on Cardiologists’ Adoption of Transcatheter Aortic Valve Replacement

    Peter W Groeneveld, Lin Yang et al.ARTICLEMedical Care2020Referências: 19

    BACKGROUND: For decades, the prevailing assumption regarding the diffusion of high-cost medical technologies has been that competitive markets favor more aggressive adoption of new treatments by health care providers (ie, the "Medical Arms Race"). However, novel regulations governing the adoption of transcatheter aortic valve replacement (TAVR) may have disrupted this paradigm when TAVR was introduced. OBJECTIVE: The objective of this study was t…

  • Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer

    Anil Vachani, Yu-Ning Wong et al.ARTICLEMedical Care2017Referências: 10

    BACKGROUND: Targeted therapy for patients with lung and colon cancer based on tumor molecular profiles is an important cancer treatment strategy, but the impact of gene mutation tests on cancer treatment and outcomes in large populations is not clear. In this study, we assessed the accuracy of an algorithm to identify tumor mutation testing in administrative claims data during a period before test-specific Current Procedural Terminology codes wer…

  • Variations in the Use of an Innovative Technology by Payer

    Andrew J Epstein, Jonathan D Ketcham et al.ARTICLEMedical Care2012Referências: 31

    BACKGROUND: Despite receiving identical reimbursement for treating heart disease patients with bare metal stents (BMS) or drug-eluting coronary stents (DES), cardiologists' use of the new technology (DES) may have varied by patient payer type as DES diffused. Payer-related factors that differ between hospitals and/or differential treatment inside hospitals might explain any overall differences by payer type. OBJECTIVES: To assess the association …

  • Geographic Variation in Implantable Cardioverter-Defibrillator Use and Heart Failure Survival

    Andrew J Epstein, Daniel Polsky et al.ARTICLEMedical Care2012Referências: 21

    BACKGROUND: Implantable cardioverter-defibrillators and cardiac resynchronization therapy-defibrillators (ICD/CRT-Ds) are evidence-based preventative treatments for many patients with heart failure (HF), yet large numbers of eligible patients remain untreated. It is uncertain if localities with more frequent ICD/CRT-D use have had better rates of HF survival. OBJECTIVES: To determine if US Hospital Referral Regions (HRRs) with larger increases in…

  • Variability in Case-mix Adjusted In-hospital Cardiac Arrest Rates

    Raina M Merchant, Lin Yang et al.ARTICLEMedical Care2012Referências: 27

    BACKGROUND: It is unknown how in-hospital cardiac arrest (IHCA) rates vary across hospitals and predictors of variability. OBJECTIVES: Measure variability in IHCA across hospitals and determine if hospital-level factors predict differences in case-mix adjusted event rates. RESEARCH DESIGN: Get with the Guidelines Resuscitation (GWTG-R) (n=433 hospitals) was used to identify IHCA events between 2003 and 2007. The American Hospital Association surv…

  • Investigating Racial Differences in Coping with Chronic Osteoarthritis Pain

    Open AccessAlvin C Jones, C Kent Kwoh et al.ARTICLEJournal of Cross-Cultural…2008Citada por: 2Referências: 28

  • Technology Diffusion, Hospital Variation, and Racial Disparities Among Elderly Medicare Beneficiaries

    Peter W Groeneveld, Sara B Laufer et al.ARTICLEMedical Care2005Referências: 30

    BACKGROUND: Low rates of technology utilization in hospitals with high proportions of black inpatients may be a remediable cause of healthcare disparities. OBJECTIVES: Our objective was to determine how differences in technology utilization among hospitals contributed to racial disparity and if temporal reduction in hospital procedure rate variation resulted in decreased racial disparity for these technologies. METHODS: We identified 2,348,952 el…